Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (620)	10/8/2006 3:15:42 PM
From: nigel bates	Read Replies (1) \| Respond to of 625

Molecular Partners And CAT Sign Cross-licence Agreement In The Fields Of Repeat Protein Technology And Ribosome Display Release Date: 26 July Cambridge, UK, and Zurich, Switzerland … Expanded opportunities for the development of novel therapeutic products Cambridge Antibody Technology (CAT) and Molecular Partners today announce that they have signed a cross-licence agreement, under which both parties obtain substantial freedom to conduct research under certain of each others' intellectual property, as well as the right to develop therapeutic, prophylactic and diagnostic products. CAT obtains access to Molecular Partners proprietary Designed Repeat Proteins (DRPs) technology and Molecular Partners gains rights to intellectual property in ribosome display, controlled by CAT, in the field of novel protein products... ... molecularpartners.com DARPins DARPins (Designed Ankyrin Repeat Protiens) are a class of novel binding proteins which has been generated by the proprietary DRP technology. DARPins are derived from natural ankyrin repeat proteins which are used in nature as versatile binding proteins with diverse functions such as cell signaling, kinase inhibition or receptor binding just to name a few. DARPins can be produced in bacterial expression systems at very high yields and they belong to the most stable proteins known. Highly specific, high-affinity DARPins to a broad range of target proteins, including human receptors, cytokines, kinases, human proteases, viruses and membrane proteins, have been selected. Affinities in the single-digit nanomolar to picomolar range are obtained by default within weeks. This is comparable to the best affinities of antibodies known to date. DARPins have been used in a wide range of applications, including ELISA, sandwich ELISA, flow cytometric analysis (FACS), immunohistochemistry (IHC), chip applications, affinity purification or Western blotting. DARPins also proved to be highly active in the intracellular compartment for example as intracellular marker proteins fused to green fluorescent protein (GFP). DARPins were further used to inhibit viral entry with IC50 in the pM range. DARPins are not only ideal to block protein-protein interactions, but also to inhibit enzymes. Proteases, kinases and transporters have been successfully ...